Update shared on30 Jul 2025
Fair value Increased 43%The sharp upward revision in Sharda Cropchem's analyst price target reflects stronger expectations for profitability, as shown by a higher net profit margin, and increased valuation confidence, as indicated by a rising future P/E, resulting in a new target of ₹1128.
What's in the News
- Board meeting scheduled to consider and approve unaudited financial results for the quarter ended June 30, 2025.
- Sharda Cropchem expected to report Q1 2026 results on July 23, 2025.
- Board recommended a final dividend of INR 6.00 per equity share for FY 2024-25, subject to shareholder approval.
- Board meeting held to consider and approve audited financial results for the quarter and year ended March 31, 2025, and to consider the final dividend for FY 2024-25.
Valuation Changes
Summary of Valuation Changes for Sharda Cropchem
- The Consensus Analyst Price Target has significantly risen from ₹790.80 to ₹1128.
- The Future P/E for Sharda Cropchem has significantly risen from 18.87x to 22.48x.
- The Net Profit Margin for Sharda Cropchem has significantly risen from 8.70% to 10.11%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.